Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · KORU Medical Systems, Inc. (KRMD)

KORU Medical Q2 revenue rises 18% to $12.0 million; gross margin guidance raised

Positive Impact 4 of 5 earnings Written later

KORU Medical reported second-quarter 2026 net revenues of $12.0 million, up 18.2%, and net income of $0.25 million, compared with a net loss a year earlier. The company raised its full-year 2026 gross margin guidance and narrowed its revenue guidance, but it also withdrew its U.S. Phesgo 510(k) application and expects international core growth to moderate.

Key points

  • Q2 2026 net revenues were $12.0 million, up from $10.2 million; net income was $0.25 million, or $0.01 per diluted share, versus a net loss of $0.2 million a year earlier.
  • Gross margin rose to 65.1% from 63.5%; full-year 2026 gross margin guidance was raised to 62% to 64%.
  • Full-year 2026 revenue guidance was narrowed to $47.5 million to $48.5 million, and year-end cash is now expected to be greater than $7.5 million after a technology acquisition.
  • The company withdrew its FreedomEDGE with Phesgo 510(k) application in the U.S. and shifted its U.S. oncology strategy to other molecules.

The filing

CompanyKORU Medical Systems, Inc. (KRMD)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:04 PM ET
Accession number0001161697-26-000188

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.